A Specific Gene May Explain How Cannabis Lowers Eye Pressure

Cannabis appears to reduce eye pressure through the GAS7 gene in humans, while the CB1 and GPR18 receptors that mediate this effect in mice do not seem to be involved in people.

Lehrer, Steven et al.·Cureus·2022·Moderate EvidenceRetrospective Cohort
RTHC-03999Retrospective CohortModerate Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Retrospective Cohort
Evidence
Moderate Evidence
Sample
N=37,046

What This Study Found

Carriers of the GAS7 gene variant (rs9913911 minor allele G) showed lower intraocular pressure with increased cannabis use (P<0.001). The CDKN2B-AS1 glaucoma gene showed no such interaction. CB1 and GPR18, which mediate cannabis IOP reduction in mice, showed no significant relationship in humans.

Key Numbers

37,046 subjects; GAS7 interaction P<0.001; CDKN2B-AS1 interaction P=0.138 (not significant); CB1 and GPR18 interactions not significant

How They Did This

Analysis of 37,046 UK Biobank subjects examining the interaction between cannabis use, genotype variants in glaucoma-associated genes (GAS7 and CDKN2B-AS1), and intraocular pressure using univariate ANOVA.

Why This Research Matters

Understanding exactly how cannabis lowers eye pressure at the genetic level could lead to targeted treatments that capture the benefit without requiring cannabis use itself.

The Bigger Picture

Cannabis has been known to lower eye pressure since the 1970s, but the mechanism has remained unclear. This study narrows the target to a specific gene, though the authors note that disadvantages of cannabis-based treatments now outweigh the advantages.

What This Study Doesn't Tell Us

Observational design. Genetic associations do not prove mechanism. UK Biobank population may not generalize globally. Cannabis use was self-reported.

Questions This Raises

  • ?Could GAS7-targeted therapies replicate cannabis's IOP-lowering effect?
  • ?Why do the receptors involved differ between mice and humans?

Trust & Context

Key Stat:
37,046 subjects analyzed
Evidence Grade:
Large cohort with genetic analysis, but observational design and the complexity of gene-environment interactions warrant caution.
Study Age:
Published in 2022
Original Title:
Cannabis, Intraocular Pressure, and the Growth Arrest-Specific 7 (GAS7) Gene: A Retrospective Analysis.
Published In:
Cureus, 14(4), e23919 (2022)
Database ID:
RTHC-03999

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-ControlFollows or compares groups over time
This study
Cross-Sectional / Observational
Case Report / Animal Study

Looks back at existing records to find patterns.

What do these levels mean? →

Frequently Asked Questions

How does cannabis lower eye pressure?

This study suggests cannabis acts through the GAS7 gene (chromosome 17) to reduce intraocular pressure in humans, which is different from the CB1 receptor mechanism found in mice.

Should cannabis be used to treat glaucoma?

The study authors concluded that while cannabis does lower eye pressure through GAS7, its "disadvantages outweigh advantages" compared to modern glaucoma treatments available today.

Read More on RethinkTHC

Cite This Study

RTHC-03999·https://rethinkthc.com/research/RTHC-03999

APA

Lehrer, Steven; Rheinstein, Peter H. (2022). Cannabis, Intraocular Pressure, and the Growth Arrest-Specific 7 (GAS7) Gene: A Retrospective Analysis.. Cureus, 14(4), e23919. https://doi.org/10.7759/cureus.23919

MLA

Lehrer, Steven, et al. "Cannabis, Intraocular Pressure, and the Growth Arrest-Specific 7 (GAS7) Gene: A Retrospective Analysis.." Cureus, 2022. https://doi.org/10.7759/cureus.23919

RethinkTHC

RethinkTHC Research Database. "Cannabis, Intraocular Pressure, and the Growth Arrest-Specif..." RTHC-03999. Retrieved from https://rethinkthc.com/research/lehrer-2022-cannabis-intraocular-pressure-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.